This trial is conducted in Europe. The aim of this trial is to investigate safety, tolerability and pharmacokinetic (the exposure of the trial drug in the body) and pharmacodynamic (the effect of the investigated drug on the body) characteristics of insulin degludec (insulin 454) and insulin degludec/insulin aspart (IDegAsp) 50 - formerly SIAM), both explorative formulations, not similar to the proposed commercial formulation, in healthy male Japanese subjects.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
32
Single dose administered subcutaneously (s.c., under the skin).
Administered subcutaneously (s.c., under the skin)
Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
Unnamed facility
Neuss, Germany
Frequency of adverse events (AEs)
Time frame: From dosing visit and until follow-up 7-21 days after last dosing visit
Area under the serum insulin concentration curve
Time frame: 0-96 hours after dosing
Area under the glucose infusion rate curve
Time frame: 0-24 hours after dosing
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.